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Abstract
Background Portal vein occlusion to increase the size of
the future liver remnant (FLR) is well established, using
portal vein ligation (PVL) or embolization (PVE) followed
by resection 4–8 weeks later. Associating liver partition
with portal vein ligation for staged hepatectomy (ALPPS)
combines PVL and complete parenchymal transection,
followed by hepatectomy within 1–2 weeks. ALPPS has
been recently introduced but remains controversial. We
compare the ability of ALPPS versus PVE or PVL for
complete tumor resection.
Methods A retrospective review of all patients undergo-
ing ALPPS or conventional staged hepatectomies using
PVL or PVE at four high-volume HPB centres between
2003 and 2012 was performed. Patients with primary liver
tumors and liver metastases were included. Primary end-
point was complete tumor resection. Secondary endpoints
include 90-day mortality, complications, FLR increase,
time to resection, and tumor recurrence.
Results Forty-eight patients with ALPPS were compared
with 83 patients with conventional-staged hepatectomies.
Eighty-three percent (40/48 patients) of ALPPS patients
achieved complete resection compared with 66 % (55/83
patients) in PVE/PVL (odds ratio 3.34, p = 0.027). Ninety-
day mortality in ALPPS and PVE/PVL was 15 and 6 %,
respectively (p = 0.2). Extrapolated growth rate was 11
times higher in ALPPS (34.8 cc/day; interquartile range
(IQR) 26–49) compared with PVE/PVL (3 cc/day; IQR2-6;
p = 0.001). Tumor recurrence at 1 year was 54 versus
52 % for ALPPS and PVE/PVL, respectively (p = 0.7).
Conclusions This study provides evidence that ALPPS
offers a better chance of complete resection in patients with
primarily unresectable liver tumors at the cost of a high
mortality. The technique is promising but should currently
not be used outside of studies and registries.
Introduction
Resection of a large tumor load in the liver may result in an
excessive removal of hepatic parenchyma leading to post-
operative liver failure and associated complications [1].
This has led to the use of portal vein manipulations to
increase the size of the putative future liver remnant (FLR).
Multiple modifications have been described including a
variety of two-stage surgeries combining removal of
tumors from the FLR with portal vein embolization (PVE)
[2, 3] or concomitant portal vein ligation (PVL) [1, 4] as
well as PVE followed by extended right hepatectomy.
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A new variant of portal vein occlusion associated with
staged hepatectomy was recently described to enhance
volume increase of the FLR [5]. This approach combines
liver partition with PVL followed by a second operation to
remove the deportalized, diseased part of the liver. The
acronym ‘‘ALPPS’’ (Associating Liver Partition with Por-
tal Vein Ligation for Staged Hepatectomy) has been pro-
posed to describe this complex procedure [6]. Initial
experience suggested that the volume increase after ALPPS
is more rapid compared with previous techniques allowing
removal of the diseased part of the liver within only
1–2 weeks after liver partition [5, 7]. Several other groups
have subsequently described the feasibility of ALPPS [8–
10], and the procedure was rapidly implemented by many
to attempt curative liver resection in patients with small
FLRs. Despite its potential to induce rapid volume
increase, ALPPS may be associated with higher postoper-
ative morbidity and mortality rates [5, 8]. An editorial and
several letters to the Annals of Surgery have sparked a
controversy over the benefits and dangers of the ALPPS
procedure [11–17].
Both PVE and PVL carry a considerable failure rate,
because only about two thirds of patients may eventually
benefit from a subsequent curative resection due to tumor
progression during the waiting interval between the two
stages or failure of the FLR to grow [2, 4, 18–20]. While
some consider tumor progression in the waiting interval
as a useful selection tool to avoid an extensive liver
resection in patients with unfavourable tumor biology
[14], others hypothesized that the long time interval
between the two stages rather than tumor biology is
responsible for the high degree of disease progression
between stages [5–9, 21]. Recently, proponents of PVE
have compared their own results with the inaugural
German series to argue against the innovation [22].
Conclusive evaluations of overall and disease-free sur-
vival comparing the two techniques will require large
patient populations, which are currently not yet available.
The purpose of this study therefore was to compare the
ability of ALPPS versus conventional two-stage approa-
ches (using PVL or PVE) to achieve complete tumor
resection using a short-time endpoint instead, allowing for
appropriate sample size and avoidance of single-centre
bias by using a multicenter design.
Materials and methods
Primary endpoint
The primary endpoint was reached when the second stage
was performed with resection of the entire tumor load with
free margins in the pathology specimen. The sample size of
patients necessary to answer the question whether ALLPS
was better than PVE/PVL to achieve complete tumor
resection was based on literature data suggesting nonpro-
gression to the second stage and thereby failure of the
entire strategy in up to a third of patients in PVE/PVL [2, 4,
8, 18, 19] and in nearly no patients for ALPPS [5, 7].
Assuming a power of 0.8 and a-error of 0.05, more than 40
patients were needed in each arm. Therefore, four inter-
national centers (Zurich, Switzerland; London, Ontario,
Canada; Buenos Aires, Argentina; Mainz, Germany) with
experience with the ALPPS procedure collaborated to pool
more than 40 consecutive ALPPS and PVE/PVL patients in
each arm. Patients who failed the primary endpoint were
classified according to four patterns of failure: (A) periop-
erative death, (B) no stage 2 because of tumor progression,
(C) no stage 2 because of failure to grow, (D) incomplete
resection (R1).
Patients
All consecutive patients, who underwent ALPPS per-
formed between January 2011 and September 2012 in the
four collaborating centres, were compared with all
patients who underwent conventional approaches (PVE/
PVL) performed between January 2003 and September
2012 in the same centres. Patients presenting with major
extrahepatic surgery or subjected to selective intra-arterial
chemotherapy and those with incomplete data on liver
volumetry or lost to follow-up were excluded. An insti-
tutional review board (IRB) approval was obtained in
each center.
Surgical technique
The surgical technique for ALPPS and conventional two-
stage liver resections associated with PVE or PVL have
been described elsewhere [5, 7]. In brief, for ALPPS,
stage 1 consists of tumor clearance of the FLR in case of
multifocal bi-lobar tumors followed by parenchymal
transection between the FLR and the diseased part of the
liver with concomitant selective PVL. In cases of single
large central tumors, transection with PVL is performed
only.
In the PVL group, the FLR is cleared of tumor and the
portal vein to the diseased hemi-liver is ligated during the
first stage without concomitant parenchymal transection, in
contrast to ALPPS. In the PVE group, patients undergo
percutaneous PVE with coils or histoacryl/lipiodol, either
alone (in case of unilobar disease) or 1–2 weeks after
tumor clearance of the FLR in patients with multifocal
bilobar tumors. In PVE and PVL, the diseased deportalized
part of the liver is removed 4–8 weeks later.
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Liver volumetry
For all groups, baseline FLR volume (FLR1, i.e., before
stage 1) and volume before stage 2 (FLR2) were measured
by computer tomography (CT) or magnetic resonance
imaging (MRI) using dedicated volume rendering software
[23, 24]. To standardize the speed of volume increase
between the two groups, a mean volume increase per day
was calculated. Since time intervals between stages dif-
fered between ALPPS and PVE/PVL, this assessment of
kinetic growth was considered an approximation. Stan-
dardized total liver volume (sTLV) was calculated
according to Vauthey [25]. The Mosteller formula was
used to calculate body surface area. Standardized FLR1
(sFLR1) and sFLR2 were calculated accordingly as FLR1/
sTLV*100 % and FLR2/sTLV*100 %, respectively.
Secondary endpoints
Secondary endpoints included: 90-day mortality, overall
and severe complications, comprehensive complication
index (CCI) [26], postoperative liver and renal failure, and
tumor recurrence up to 12 months. The study was not
powered to detect differences in secondary endpoints.
Complications were recorded using the Clavien-Dindo
classification [27]; a severe complication was defined as
grade C IIIB (requirement of invasive procedures under
general anesthesia to correct a complication). The novel
CCI was reported to summarize for the first time all post-
operative complications and their severities over both
stages into one single continuous scale (www.assessurgery.
com) [26]. Postoperative liver failure was defined accord-
ing to the 50/50 criteria [28], renal failure as an increase of
creatinine within 48 h after surgery to more than 1.4 of the
preoperative level [29]. Tumor progression and recurrence
were assessed up to 12 months starting to count from the
first stage in both arms.
American Society of Anesthesiologists (ASA) physical
status classification system was coded based on the defi-
nition provided on the ASA webpage (www.asahq.org).
Charlson score was determined using a Microsoft Excel
macro [30]. Type of tumor and histology was coded based
on pathology source documents. Tumor size and number of
lesions were defined through primary review of imaging by
experienced radiologists in each center.
Statistical analysis
The distribution of variables was analyzed using means and
standard deviation (SD) for normally distributed, and
median and interquartile ranges (IQR) for nonnormally
distributed data. Data were tested for normality using
quantile–quantile plots of dependent variables.
The primary endpoint (complete resection with R0
margins) was compared between the two groups (ALPPS
vs. PVE/PVL) using uni- and multivariate logistic regres-
sion models with the primary endpoint as the dependent
and treatment group as the independent variable. We
adjusted for following potential confounders: age, previous
abdominal surgery (yes/no), type of tumor, FLR1/body
weight (BW), and liver macrosteatosis (yes/no). Uni- and
multivariate linear as well as logistic regression analyses
were performed for the secondary endpoints. Data were
reported as point estimates, 95 % confidence intervals (CI),
and p values (B0.05 considered as significant).
Kaplan–Meier survival curves were constructed for time
to proceed to the second stage and progression free sur-
vival. Associating liver partition with portal vein ligation
for staged hepatectomy and PVE/PVL were compared
using log-rank statistics.
All statistical analyses were performed using STATA 11
(Stata Corp., College Station, TX). Figures were made
using Graph Pad Prism (Graph Pad Software, La Jolla,
CA).
Results
A total of 170 patients with liver tumors undergoing liver
resections in two stages at the four centres were analyzed.
Thirty-nine patients were excluded because of simulta-
neous extrahepatic surgery (n = 4), placement of selective
intra-arterial perfusion pumps (n = 14), had benign tumors
(n = 7), had no appropriate imaging (n = 13), or were lost
to follow-up within 3 months (n = 1). A total of 131
patients were eventually included: 48 with ALPPS and 83
with PVE/PVL (Fig. 1).
Comparison of patient population demographics, mor-
bidity, and comorbidity data showed a higher percentage of
mild hepatic macrosteatosis (\30 %) in the ALPPS group
as well as difference in the number of enrolled patients per
centre (Table 1). Future liver remnant in cubic centimetres
and sFLR in percent before stage 1 (FLR1 and sFLR1), as
well FLR to body weight ratio before stage 1 (FLR1/BW)
were not statistically different between both groups. Need
for biliary reconstruction was higher in ALPPS in stage 1
and higher in PVE/PVL in stage 2, but in both stages,
comparable (Table 2).
Eighty-three percent (40/48) of ALPPS patients achieved
complete resection compared with 66 % (55/83) in the PVE/
PVL group. Seventeen percent (8/48) of ALPPS patients
failed the primary endpoint due to (A) mortalities (n = 7)
and due to one patient with (D) incomplete resection (R1)
(Table 3).
In comparison, 28 of 83 patients (34 %) in the PVE/PVL
group did not reach complete resection because of
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(A) postoperative mortality (n = 5), (B) liver (n = 4) or
systemic (n = 9) tumor progression, (C) failure of the FLR
to grow (n = 6) and R1 resection in 4 patients (Table 3).
Results of the multivariate analysis for primary and sec-
ondary endpoints and the odds ratios of patients with ALPPS
for these endpoints, unadjusted and adjusted for age, previous
abdominal surgery, type of tumor, FLR1/BW, and liver
macrosteatosis are shown in Table 4; ALPPS was more
likely to achieve complete resection (adjusted OR 3.34, CI
1.15-9.74, p = 0.027).
Mortality at 90 days was 15 % (7/48) in ALPPS com-
pared with 6 % (5/83) in PVE/PVL, i.e., the corrected odds
for perioperative death were 2.7 time higher (p = 0.2;
Table 4). Severe complications were more common in
ALPPS after both steps compared with PVE/PVL, but the
numbers were too small to show significance. In both
groups, liver failure occurred only after stage 2 at 13 and
9 % in ALPPS and PVE/PVL, respectively. There was a
trend towards more overall complications in the ALPPS
group according to the new CCI (p = 0.05). There were no
differences in the incidence of postoperative bile leaks. The
incidence of acute renal failure after stage 1 in ALPPS
seemed high at 8 % (4/48), but renal failure after stage 2
was not different between groups at 10 and 15 % for
ALLPS and PVE/PVL, respectively (Table 4).
Median FLR2, sFLR2, and FLR2/BW (i.e., before stage
2) were higher in ALPPS than in PVE/PVL (Table 5). Each
ALPPS patient reached the 30 % sFLR cutoff recom-
mended for safer liver surgery [1] before stage 2, whereas
many PVE/PVL cases did not (Fig. 2). Increase of FLR
volume between stage 1 and 2 in both groups was signif-
icant (p B 0.001) (Fig. 2). The median increase of FLR
between stages was 34 % for PVE/PVL and 77 % for
ALLPS (Table 5). Extrapolated kinetic growth for ALPPS
was 11 times higher (34.8 cc/day, IQR 26.4–48.5) com-
pared with PVE/PVL (2.78 cc/day, IQR 1.69–5.81; Fig. 2;
Table 5).
Whereas ALPPS patients proceeded to resection faster
(Fig. 3a), tumor recurrence occurred at a comparable rate
in both groups at 12 months with 54 % in ALPPS and
52 % in PVE/PVL (Fig. 3b).
Discussion
Patients with primarily unresectable liver tumors have a
poor prognosis with a near zero 5-year survival despite the
availability of modern chemotherapy. Because only a
curative resection offers a chance of long-term survival,
strategies using staged hepatectomies have been developed
over the past two decades, however, with limited success
[2, 4, 18, 19]. It has been suggested that the recently
introduced ALPPS procedure offers new horizons to
remove extensive tumors localized to the liver by stimu-
lating regeneration of the healthy part of the liver at an
unprecedented pace and extent [5, 6]. This enthusiasm has
been challenged by others due to lack of convincing data
and fear of an increased rate of perioperative complications
[12, 14].
While definitive evidence for a long-term benefit in sur-
vival of ALPPS will be lacking for a long time due to the
large numbers of patients necessary to show a difference, it is
critical to evaluate this approach before it is widely used or
abandoned without objectively weighing its merits. While an
attempt has been made to compare PVE to the published data
about ALPPS [22], no large comparative study is currently
Fig. 1 Flowchart of patients
screened and included in the
study
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available. At this point, centres have reported small case
series, mostly with a focus on feasibility and technical
variations, such as the description of a laparoscopic approach
[16], providing only anecdotal information. Therefore, we
designed a study with the endpoint complete resection,
which is a relevant and sufficiently powered, short-term
Table 1 Characteristics of
patients with unresectable liver
tumors cohorts undergoing
PVE/PVL or ALPPS
All data are given in proportions
or in medians with interquartile
ranges (IQR)
PVE/PVL portal vein
embolization/portal vein
ligation, ALPPS associating
liver partition with portal vein
ligation for staged hepatectomy,
ASA American Society of
Anesthesiologists Physical
Status Classification, BMI body
mass index, INR international
normalized ratio, CRLM
colorectal liver metastasis, HCC
hepatocellular carcinoma, IHCC
intrahepatic
cholangiocarcinoma, PHCC
perihilar cholangiocarcinoma,
SOS sinusoidal obstruction
syndrome, CASH
chemotherapy-associated
steatohepatitis, CH Switzerland,
CA Canada, AR Argentina, GE
Germany
Characteristics PVE/PVL group ALPPS group p value
Stage 1: n = 83 In stage 1: n = 48
Stage 2: n = 54 In stage 2: n = 48
Age (year) 61 (54–69) 57 (48.5–65) 0.11
Sex, male/female 57 (68.7 %)/26 (31.3 %) 29 (60.4 %)/19 (39.6 %) 0.34
ASA 0.07
B2 57 (68.7 %) 40 (83.3 %)
[2 26 (31.3 %) 8 (16.7 %)
Charlson index 7 (6–9) 8 (4–9) 0.47
Diabetes mellitus 11 (13.3 %) 4 (8.3 %) 0.4
Type of tumor 0.68
CRLM 48 (57.8 %) 26 (54.2 %)
HCC 7 (8.4 %) 3 (6.3 %)
Biliary carcinoma 16 (19.3 %) 10 (20.8 %)
IHCC 5 (6 %)
PHCC 11 (13.2 %) 2 (4.2 %)
Other malignant tumors 12 (14.5 %) 7 (14.6 %)
BMI (kg/m2) 25.4 (23.1–28.7) 25.9 (23.4–28.8) 0.95
Preoperative chemotherapy 44 (53 %) 28 (58.3 %) 0.56
Creatinine baseline (lmol/L) 71 (62–86) 71 (62–82.2) 0.49
Bilirubin baseline (lmol/L) 12 (8–20) 11 (6.6–15.7) 0.09
INR baseline 1 (1–1.1) 1 (1–1.1) 0.52
Preoperative biliary drainage
In stage 1 11 (13.3 %) 4 (8.3 %) 0.44
In stage 2 12 (22.2 %) 5 (10.4 %) 0.27
Previous liver surgery 16 (19.3 %) 9 (18.8 %) 0.94
Multifocal bilobar tumor 56 (67.5 %) 29 (60.4 %) 0.42
Number of lesions
\5 50 (60.2 %) 23 (47.9 %) 0.09
C5 29 (34.9 %) 25 (52.1 %)
Missing 4 (4.9 %) 0 %
Histology
No histology 29 (34.9) –
Normal 25 (30.2 %) 17 (35.4 %) 0.10
Macrosteatosis
[30 % 8 (9.6 %) 2 (4.2 %) 0.026
\30 % 17 (20.5 %) 21 (43.7 %) 0.35
Fibrosis 4 (4.8 %) 6 (12.5 %) –
SOS 0 % 2 (4.2 %) –
CASH 0 % 0 %
Centers
Zurich, CH 40 (48.2 %) 18 (37.5 %) 0.24
London Ontario, CA 21 (25.3 %) 5 (10.4 %)
Buenos Aires, AR 12 (14.5 %) 15 (31.3 %)
Mainz, GE 10 (12 %) 10 (20.8 %)
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surgical endpoint. The only chance of cure for this high-risk
population, which often is offered only palliative chemo-
therapy, is a complete extirpation of the tumor, which
requires staged procedures combining PVE or PVL and
major hepatectomy at a later stage. This endpoint was chosen
because achieving early complete resection is the indisput-
able basis for long-term survival.
The putative advantage of ALPPS is a faster regenera-
tion of the FLR, which enables surgeons to proceed with
the second stage before the development of adhesions or
tumor progression. This key feature of ALLPS has been
questioned by a few proponents of PVE, who claimed that
the volume increase observed in ALPPS is similar to what
can be achieved after right PVE, particularly with the
Table 2 Operative characteristics of patients with unresectable liver tumors cohorts undergoing PVE/PVL or ALPPS
Stage 1 PVE/PLV group ALPPS group p value
n = 83 n = 48
Type of surgery
PVO 83 (100 %)
PVE 51 (62.4 %)
PVL 32 (38.6 %)
ALPPS – 48 (100 %)
Size of FLR1 (cc) 389 (324–470) 367 (286–440) 0.10
Size of sFLR1 0.24 (0.18–0.31) 0.23 (0.18–0.29) 0.07
FLR1/BW (cc/kg) 0.53 (0.39–0.67) 0.47 (0.39–0.59) 0.06
Cleaning of the FLR 55 (66 %) 28 (58.3) 0.27
Biliary reconstruction 0 (0 %) 8 (16.7 %) \0.001
Hepaticojejunostomy
One duct 5
Multiple ducts 3
Stage 2 PVE/PVL group ALPPS group p value
n = 54 n = 48
Size of FLR2 (cc) 530 (454–648) 639 (525–786) 0.007
Size of sFLR2 0.35 (0.27–0.45) 0.41 (0.34–0.47) 0.003
FLR2/BW (cc/kg) 0.73 (0.56–0.96) 0.84 (0.73–0.99) 0.005
Biliary reconstruction 15 (27.8 %) 4 (8.3 %) 0.06
Hepaticojejunostomy
One duct 9 2
Multiple ducts 6 2
All data are given in proportions or in medians with interquartile ranges (IQR)
PVO portal vein occlusion, PVE/PVL portal vein embolization, portal vein ligation, ALPPS associating liver partition with portal vein ligation for
staged hepatectomy, FLR1 future liver remnant volume prior to stage 1, FLR2 future liver remnant volume prior to stage 2, sFLR1 standardized
future liver remnant prior to stage 1, sFLR2 standardized future liver remnant prior to stage 2, FLR1/BW future liver remnant to body weight ratio
prior to stage 1, FLR2/BW future liver remnant to body weight ratio prior to stage 2
Table 3 Reasons for failure of
the primary endpoint
Reason for failure PVE/PVL ALPPS
n = 83 n = 48
A. Perioperative death (3 months) n (%) 5 (6 %) 7 (15 %)
B. No stage 2 because of tumor progression n (%) 13 (16 %) 0
Liver n 4 0
Systemic n 9 0
C. No stage 2 because of failure to grow n (%) 6 (7 %) 0
D. Incomplete resection (R1) n (%) 4 (5 %) 1 (2 %)
Patients who failed primary endpoint n (%) 28 (34 %) 8 (17 %)
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Table 4 Clinical outcomes of the two patient cohorts using logistic and linear regression analysis correcting for important confounders
PVE/PVL group ALPPS group Unadjusted odds ratio Adjusted odds ratio
In stage 1: n = 83 In stage 1: n = 48 (95 % CI, p value) (95 % CI, p value)
In stage 2: n = 54 In stage 1: n = 48
(proportion) (proportion)
Primary endpoint
Complete resection (R0) 55 (66.3 %) 40 (83.3 %) 2.55 3.34
(1.05–6.17, p = 0.039) (1.15–9.74, p = 0.027)
Secondary endpoints
In-hospital mortality after stage 1 0 % 0 % – –
In-hospital mortality after stage 2 2 (3.7 %) 7 (14.6 %) 4.4 2.47
(0.9–22.5, p = 0.072) (0.34–17.45, p = 0.368)
90-day mortality 5 (6 %) 7 (14.6 %) 2.66 2.65
(0.8–8.9, p = 0.112) (0.6–11.9, p = 0.201)
Any complication after stage 1 21 (25.3 %) 21 (43.8 %) 2.3 2.16
(1.08–4.89, p = 0.031) (0.86–5.46, p = 0.103)
Any complication after stage 2 40 (74.1 %) 35 (72.9 %) 0.95 0.64
(0.39–2.29, p = 0.907) (0.22–1.84, p = 0.407)
Severe complications (CIIIB) after stage 1 2 (2.4 %) 7 (14.6 %) 6.9 –
(1.4– 34.8, p = 0.019)
Severe complications (C IIIB) after stage 2 8 (14.8 %) 13 (27.1 %) 2.13 2.0
(0.8–5.7, p = 0.131) (0.6–6.5, p = 0.238)
PVE/PVL group ALPPS group Unadjusted difference Adjusted difference
In stage 1: n = 83 In stage 1: n = 48 (95 % CI, p value) (95 % CI, p value)
In stage 2: n = 54 In stage 2: n = 48
Median (IQR) Median (IQR)
Comprehensive
complications index (CCI) for both stages
20.9 (8.7–30.8) 26.2 (8.7–44.9) 10.9 11.5
(-0.3 to 22.0, p = 0.057) (-0.2 to 23.3, p = 0.054)
PVE/PVL group ALPPS group Unadjusted odds ratio Adjusted odds ratio
In stage 1: n = 83 In stage 1: n = 48 (95 % CI, p value) (95 % CI, p value)
In stage 2: n = 54 In stage 1: n = 48
(proportion) (proportion)
Postoperative liver failure after stage 1a 0 % 0 % – –
Postoperative liver failure after stage 2a 5 (9.3 %) 6 (12.5 %) 1.3 1.1
(0.4–4.9, p = 0.651) (0.2–4.5, p = 0.934)
Bile leak after stage 1 2 (2.4 %) 1 (2.1 %) – –
Bile leak after stage 2 9 (16.7 %) 10 (20.8 %) 1.3 1.3
(0.5–3.6, p = 0.59) (0.4–4.0, p = 0.685)
Acute kidney failure after stage 1 2 (2.4 %) 4 (8.3 %) – –
Acute kidney failure after stage 2 8 (14.8 %) 5 (10.4 %) 0.7 0.35
(0.2–2.2, p = 0.508) (0.1–1.8, p = 0.2)
Data are reported as proportion or medians with IQR, differences as point estimates with 95 % confidence intervals (CI) and p values (B0.05
considered as significant)
Adjusted for age, previous abdominal surgery (non-liver), different diseases, FLR1/BW (prior to stage 1), and liver steatosis (yes/no). No
statistical analysis if less than 5 patients
a By 50–50 criteria, see ‘‘Materials and methods’’ Section
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inclusion of segment four [14]. The results of this com-
parative analysis of 131 cases provide overwhelming evi-
dence for a higher degree of liver regeneration with the
ALPPS procedure, as previously suggested in small case
series [5, 7, 8]. Of course, the limitation of our standardi-
zation of kinetic growth is the fact that is based on different
time periods between stages as the denominator in ALPPS
and PVE/PVL, shorter in ALPPS, longer in PVE/PVL.
However, this study contributes to the evidence that rapid
hypertrophy in ALPPS is real.
It has been challenged that reduced waiting time to
proceed with complete resection may represent an onco-
logical advantage. Several clinicians have argued that a
long waiting interval in the conventional approaches is
rather a selection tool to identify those who may best
benefit from the completion hepatectomy [14]. Another
concern raised was that livers are strongly manipulated in
the ALPPS procedure, which may promote tumor cell
dissemination by detaching cells into the systemic and
pulmonary circulation. Additionally, the local and systemic
release of growth factors may further stimulate tumor
growth [14]. This study does not corroborate such concerns
at least in the short-term, because recurrence occurred at a
similar rate in both groups.
In the inaugural manuscript from Germany, ALPPS was
successful in achieving complete resection at the cost of a
postoperative mortality rate of 12 % (3/25) [5], which is
also in the range of the mortality observed in this study.
While these figures are undoubtedly high, it is difficult to
define what is acceptable mortality in a population pre-
senting with such advanced malignancies and the potential
for a curative surgical approach. Postoperative mortality
has to be balanced with the risk of incomplete resection
using the conventional approaches or in some cases the
lack of alternative therapies in cases when the FLR is
extremely small. Staged hepatectomies, including PVE or
PVL, are associated with a postoperative mortality rate
between 6 and 8 % [2, 4, 18, 19] compared with a 3–6 %
mortality rate for conventional major hepatectomies [31].
The mortality of PVE/PVL in this series of 5 of 83 (6 %) is
within the reported range. The 90-day mortality of 14.6 %
in our cohort represents the initial experience with the
ALPPS operation and, without any doubt, includes our
Table 5 Analysis of volume changes in patients undergoing ALPPS and PVE/PVL using linear regression analysis
PVE/PVL group ALPPS group Unadjusted difference Adjusted difference
In stage 1: n = 83 In stage 1: n = 48 (95 % CI, p value) (95 % CI, p value)
In stage 2: n = 54 In stage 2: n = 48
Median (IQR) Median (IQR)
FLR2 (before stage 2) (cc) 530 (454–648) 638.5 (525–785.5) 93.7 130.9
(19.9–167.6, p = 0.013) (61.7–200.1, p \ 0.001)
sFLR2 (before stage 2) 0.35 (0.27–0.45) 0.41 (0.34–0.47) 0.05 0.08
(0.01–0.09, p = 0.019) (0.05–0.11, p \ 0.001)
FLR2/BW ratio before stage 2 (cc/kg) 0.73 (0.56–0.96) 0.84 (0.73–0.99) 0.1 0.18
(0.003–0.19, p = 0.042) (0.11–0.25, p \ 0.001)
Increase of FLR between stage 1 and 2 (%) 34.1 (17.4–55.7) 77.4 (52.8–101.7) 46.5 42
(33.8–59.2, p \ 0.001) (30.1–53.9, p \ 0.001)
Extrapolated kinetic growth (cc/day) 2.78 (1.69–5.81) 34.8 (26.4–48.5) 34.4 34
(30.2–38.6, p \ 0.001) (29.4–38.5, p \ 0.001)
Data are reported as medians with IQR, differences as point estimates with 95 % confidence intervals (CI) and p values (B0.05 considered as significant)
Adjusted for age, previous abdominal surgery (non-liver), different diseases, FLR1/BW (prior to stage 1) and liver steatosis (yes/no). All results are
reported as median and interquartile range
FLR2 future liver remnant prior to stage 2, sFLR2 standardized future liver remnant prior to stage 2, FLR2/BW ratio future liver remnant divided by body
weight prior to stage 2
Fig. 2 Extrapolation of kinetic growth by depicting the increase of
the standardized future liver remnant volumes (sFLR) determined by
volumetry before stage 1 (middle) and before stage 2 in ALPPS (left)
and PVE/PVL (right). The interrupted line shows the common
clinical cutoff of 30 % for safer liver surgery
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learning curve. In addition, this cohort inevitably has a
selection bias, because patients may have been offered
ALPPS because they were deemed inoperable by a con-
ventional two-stage approach.
Liver failure, abdominal sepsis, and biliary leaks after
surgery were the leading causes for severe complications
and death in both groups, which is not different to what has
been observed after conventional liver surgery [32]. Severe
complications were rare after stage 1 in PVE/PVL, but
occurred both after stage 1 and stage 2 in ALPPS. A risk
factor analysis for complications failed to identify signifi-
cant risk factors, probably due to the small sample size,
although, of interest, five of seven fatalities in the ALPPS
group occurred in patients older than 70 years of age and
five of seven fatalities occurred in patients with primary
liver tumors. Considering the high morbidity and mortality,
we caution the application of ALPPS as summarized in
Table 6. With later knowledge and technical develop-
ments, revisions of these recommendations will become
necessary.
This study is not without limitations. For example, the
retrospective methodology yields a bias in the selection of
patients in each group. ALPPS was chosen in an attempt to
offer a curative operation to patients with extended liver
malignancies, who had few options, but were interested in
an aggressive, potentially curative, surgical approach. Also
the time periods of patient inclusion differed, which is
frequently unavoidable when new technologies are evalu-
ated. However, we meticulously included all approaches
involving the induction of liver hypertrophy by portal vein
occlusion performed in the respective time periods at the
respective centres. To address the concern about selection
bias, we performed a multivariate analysis adjusting for
known confounders. Secondly, the size of groups allowed
us to evaluate our primary endpoint but did not provide
enough power to convincingly address the differences in
overall and disease-free survival, as well as morbidity.
Finally, the majority of cases were performed very recently
without sufficiently long follow-up to report long-term
oncological results.
In conclusion, this study suggests that ALPPS offers a
better chance of complete resection in patients with pri-
marily unresectable liver tumors. This approach deserves
further evaluation. Therefore, we implemented a registry
(www.alpps.net) and initiated a multicenter RCT (www.
clinicaltrials.gov; NCT 01775267). For the time being, due
to the higher risk of morbidity and fatalities, we caution the
widespread application of ALPPS outside of experienced
centres.
Table 6 Recommendations for ALPPS
1. Best indication is a large tumor load with marginal future liver
remnant (FLR) and curative intent
2. Should be used with caution in patients older than 70 years
3. Should be used with caution in patients with primary liver
tumors (HCC, CCC)
4. Surgical team should have experience in complex liver surgery
5. Experience with in situ split or live donor liver transplantation
might be of benefit
6. Avoid concomitant major abdominal surgery such as
pancreatectomies and rectal resection
7. Informed consent mentioning higher perioperative morbidity
and mortality should be obtained
8. Registration of patients in an international registry (www.alpps.
net)
9. Should be preferentially performed in the setting of a
prospective trial
Fig. 3 a Kaplan–Meier graph demonstrating progression to stage 2
surgery comparing ALLPS with PVE/PVL. Numbers of patients at
risk in the bottom line. b Kaplan–Meier graph demonstrating time to
progression or recurrence or persistence of tumor after resection
comparing ALLPS with PVE/PVL. Numbers of patients at risk in the
bottom line
1518 World J Surg (2014) 38:1510–1519
123
Acknowledgment This study was supported by the University of
Zurich (Klinischer Forschungsschwerpunkt: Non-resectable Liver
Tumors) and the Liver and Gastro-intestinal Disease Foundation
(LGID) Swiss HPB Center, Zurich. We thank Sabine Kern, RN, and
Lisette Paratore for their help in data collection for this manuscipt.
References
1. Clavien PA, Petrowsky H, DeOliveira ML et al (2007) Strategies
for safer liver surgery and partial liver transplantation. N Engl J
Med 356:1545–1559
2. Jaeck D, Oussoultzoglou E, Rosso E et al (2004) A two-stage
hepatectomy procedure combined with portal vein embolization
to achieve curative resection for initially unresectable multiple
and bilobar colorectal liver metastases. Ann Surg 240:1037–1049
discussion 1049–1051
3. Adam R, Laurent A, Azoulay D et al (2000) Two-stage hepa-
tectomy: a planned strategy to treat irresectable liver tumors. Ann
Surg 232:777–785
4. Kianmanesh R, Farges O, Abdalla EK et al (2003) Right portal
vein ligation: a new planned two-step all-surgical approach for
complete resection of primary gastrointestinal tumors with mul-
tiple bilateral liver metastases. J Am Coll Surg 197:164–170
5. Schnitzbauer AA, Lang SA, Goessmann H et al (2012) Right
portal vein ligation combined with in situ splitting induces rapid
left lateral liver lobe hypertrophy enabling 2-staged extended
right hepatic resection in small-for-size settings. Ann Surg
255:405–414
6. de Santibanes E, Clavien PA (2012) Playing Play-Doh to prevent
postoperative liver failure: the ‘‘ALPPS’’ approach. Ann Surg
255:415–417
7. Alvarez FA, Ardiles V, Sanchez Claria R et al (2013) Associating
liver partition and portal vein ligation for staged hepatectomy
(ALPPS): tips and tricks. J Gastrointest Surg 17:814–821
8. Knoefel WT, Gabor I, Rehders A et al (2013) In situ liver tran-
section with portal vein ligation for rapid growth of the future
liver remnant in two-stage liver resection. Br J Surg 100:388–394
9. Li J, Girotti P, Konigsrainer I et al (2013) ALPPS in right tri-
sectionectomy: a safe procedure to avoid postoperative liver
failure? J Gastrointest Surg 17:956–961
10. Cavaness KM, Doyle MB, Lin Y et al (2013) Using ALPPS to
induce rapid liver hypertrophy in a patient with hepatic fibrosis
and portal vein thrombosis. J Gastrointest Surg 17:207–212
11. Clavien PA, Lillemoe KD (2012) Note from the editors on the
ALPPS e-Letters-to-the-Editor. Ann Surg 256:552
12. Dokmak S, Belghiti J (2013) Which limits to the ‘‘ALPPS’’
approach? Ann Surg 256:e6 author reply e16-17
13. Narita M, Oussoultzoglou E, Ikai I et al (2012) Right portal vein
ligation combined with in situ splitting induces rapid left lateral
liver lobe hypertrophy enabling 2-staged extended right hepatic
resection in small-for-size settings. Ann Surg 256:e7–e8 author
reply e16-17
14. Aloia TA, Vauthey JN (2012) Associating liver partition and
portal vein ligation for staged hepatectomy (ALPPS): what is
gained and what is lost? Ann Surg 256:e9 author reply e16-19
15. Jain HA, Bharathy KG, Negi SS (2012) Associating liver parti-
tion and portal vein ligation for staged hepatectomy: will the
morbidity of an additional surgery be outweighed by better
patient outcomes in the long-term? Ann Surg 256:e10 author
reply e16-17
16. Machado MA, Makdissi FF, Surjan RC (2013) ALPPS procedure
with the use of pneumoperitoneum. Ann Surg Oncol
20(5):1491–1493
17. Andriani OC (2012) Long-term results with associating liver
partition and portal vein ligation for staged hepatectomy (AL-
PPS). Ann Surg 256:e5 author reply e16-19
18. Tsai S, Marques HP, de Jong MC et al (2010) Two-stage strategy
for patients with extensive bilateral colorectal liver metastases.
HPB (Oxford) 12:262–269
19. Wicherts DA, Miller R, de Haas RJ et al (2008) Long-term results
of two-stage hepatectomy for irresectable colorectal cancer liver
metastases. Ann Surg 248:994–1005
20. Brouquet A, Abdalla EK, Kopetz S et al (2011) High survival rate
after two-stage resection of advanced colorectal liver metastases:
response-based selection and complete resection define outcome.
J Clin Oncol 29:1083–1090
21. Sala S, Ardiles V, Ulla M et al (2012) Our initial experience with
ALPPS technique: encouraging results. Updat Surg 64:167–172
22. Shindoh J, Vauthey JN, Zimmitti G et al (2013) Analysis of the
efficacy of portal vein embolization for patients with extensive
liver malignancy and very low future liver remnant volume,
including a comparison with the associating liver partition with
portal vein ligation for staged hepatectomy approach. J Am Coll
Surg 217:126–133 discussion 133-134
23. van der Vorst JR, van Dam RM, van Stiphout RS et al (2010)
Virtual liver resection and volumetric analysis of the future liver
remnant using open source image processing software. World J
Surg 34:2426–2433. doi:10.1007/s00268-010-0663-5
24. Dello SA, Stoot JH, van Stiphout RS et al (2011) Prospective
volumetric assessment of the liver on a personal computer by
nonradiologists prior to partial hepatectomy. World J Surg
35:386–392. doi:10.1007/s00268-010-0877-6
25. Vauthey JN, Abdalla EK, Doherty DA et al (2002) Body surface
area and body weight predict total liver volume in Western
adults. Liver Transpl 8:233–240
26. Slankamenac K, Graf R, Barkun J et al (2013) The comprehen-
sive complication index: a novel continuous scale to measure
surgical morbidity. Ann Surg 258:1–7
27. Dindo D, Demartines N, Clavien PA (2004) Classification of
surgical complications: a new proposal with evaluation in a
cohort of 6336 patients and results of a survey. Ann Surg
240:205–213
28. Balzan S, Belghiti J, Farges O et al (2005) The ‘‘50-50 criteria’’
on postoperative day 5: an accurate predictor of liver failure and
death after hepatectomy. Ann Surg 242:824–828 discussion
828-829
29. Lameire N, Van Biesen W, Vanholder R (2008) Acute kidney
injury. Lancet 372:1863–1865
30. Hall WH, Ramachandran R, Narayan S et al (2004) An electronic
application for rapidly calculating Charlson comorbidity score.
BMC Cancer 4:94
31. Asiyanbola B, Chang D, Gleisner AL et al (2008) Operative
mortality after hepatic resection: are literature-based rates
broadly applicable? J Gastrointest Surg 12:842–851
32. Breitenstein S, DeOliveira ML, Raptis DA et al (2010) Novel and
simple preoperative score predicting complications after liver
resection in noncirrhotic patients. Ann Surg 252:726–734
World J Surg (2014) 38:1510–1519 1519
123
